Adjuvant therapy in colon cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol. Biomarkers Prev.18(6), 1695–1698 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon, France (2010).
   Google Scholar
• Chao A, Thun MJ, Connell CJ et al. Meat consumption and risk of colorectal cancer. JAMA293(2), 172–182 (2005).
   PubMed Web of Science ®Google Scholar
• Longnecker MP, Orza MJ, Adams ME, Vioque J, Chalmers TC. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer. Cancer Causes Control1(1), 59–68 (1990).
   PubMed Web of Science ®Google Scholar
• Levin KE, Dozois RR. Epidemiology of large bowel cancer. World J. Surg.15(5), 562–567 (1991).
   PubMed Web of Science ®Google Scholar
• Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer92(3), 434–444 (2005).
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res.5(2), 165–170 (2007).
   PubMedGoogle Scholar
• Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol. Rep.25(6), 1691–1697 (2011).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann. Surg.199(4), 375–382 (1984).
   PubMed Web of Science ®Google Scholar
• Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med.124(7), 979–994 (2000).
   PubMed Web of Science ®Google Scholar
• Steinberg SM, Barwick KW, Stablein DM. Importance of tumor pathology and morphology in patients with surgically resected colon cancer. Findings from the Gastrointestinal Tumor Study Group. Cancer58(6), 1340–1345 (1986).
   PubMed Web of Science ®Google Scholar
• Lim SB, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis. Colon Rectum53(4), 377–384 (2010).
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
   PubMed Web of Science ®Google Scholar
• Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes examined and staging accuracy in colorectal carcinoma. J. Clin. Oncol.17(9), 2896–2900 (1999).
   PubMed Web of Science ®Google Scholar
• Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J. Clin. Oncol.21(15), 2912–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Tepper JE, O’Connell MJ, Niedzwiecki D et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J. Clin. Oncol.19(1), 157–163 (2001).
   PubMed Web of Science ®Google Scholar
• Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch. Pathol. Lab. Med.124(7), 1016–1025 (2000).
   PubMedGoogle Scholar
• West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J. Clin. Oncol.28(2), 272–278 (2010).
   PubMed Web of Science ®Google Scholar
• No authors listed. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA264, 1444–1450 (1990).
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol.22(16), 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med.122(5), 321–326 (1995).
   PubMed Web of Science ®Google Scholar
• Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol.21(15), 2896–2903 (2003).
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol.45(4), 291–297 (2000).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19(8), 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19(21), 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352(26), 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br. J. Cancer94(8), 1122–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol.29(11), 1465–1471 (2011).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet352(9138), 1413–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet352(9138), 1407–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet355(9209), 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol.27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin. Oncol.25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Ychou M, Raoul JL, Douillard JY et al. A Phase III randomized trial of LV5-FU2 + irinotecan versus LV5-FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann. Oncol.20(4), 674–680 (2009).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Bjarnason GA, Hickish T et al. Randomized double blind (DB) placebo (Plcb) controlled Phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX-4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J. Clin. Oncol.24(18S), 3507 (2006).
   Google Scholar
• Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systemic review from the Cancer Care Ontario Program in Evidence Based Cares Gastrointestinal Cancer Disease Site Group. J. Clin. Oncol.22(10), 1200 (2004).
   Google Scholar
• Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer after complete resection. Cancer Prev. Control1, 379–392 (1997).
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/ Dukes B2 colon cancer. J. Clin. Oncol.13, 2936–2943 (1995).
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol.22(10), 1797–1806 (2004).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J. Clin. Oncol.17(5), 1356–1363 (1999).
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D et al. A randomized comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16(4), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Sargent DJ, Smyrk TC. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol.28(18 Suppl.), (2010) (Abstract CRA3507).
   Google Scholar
• Wolmark N, Yothers G, O’Connell MJ et al. A Phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol.27(Suppl. 18), (2009) (Abstract LBA4).
   Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol.29(1), 11–16 (2010).
   PubMed Web of Science ®Google Scholar
• De Gramont A, Van Cutsem E, Tabernero J et al. AVANT: results from a randomized, three-arm multinational Phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 362).
   Google Scholar
• Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J. Clin. Oncol.29(1), 1–4 (2010).
   PubMedGoogle Scholar
• Feliu J, Sereno M, Castro JD, Belda C, Casado E, Gonzalez-Baron M. Chemotherapy for colorectal cancer in the elderly: whom to treat and what to use. Cancer Treat. Rev.35(3), 246–254 (2009).
   PubMedGoogle Scholar
• Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med.345(15), 1091–1097 (2001).
   PubMed Web of Science ®Google Scholar
• Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med.136(5), 349–357 (2002).
   PubMed Web of Science ®Google Scholar
• Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA294(21), 2703–2711 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol.24(25), 4085–4091 (2006).
   PubMed Web of Science ®Google Scholar
• Wildes TM, Kallogjeri D, Powers B et al. The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. J. Geriatr. Oncol.1(2), 48–56 (2010).
   PubMedGoogle Scholar
• Kahn KL, Adams JL, Weeks JC et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA303(11), 1037–1045 (2010).
   PubMed Web of Science ®Google Scholar
• Obeidat NA, Pradel FG, Zuckerman IH, DeLisle S, Mullins CD. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am. J. Geriatr. Pharmacother.7(6), 343–354 (2009).
   PubMedGoogle Scholar
• Sargent D, Shi Q, Yothers G et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur. J. Cancer47(7), 990–996 (2011).
   PubMedGoogle Scholar
• Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases; results from two Phase I studies. J. Clin. Oncol.21, 3955–3964 (2003).
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patietns treated with first line bevacizumab. Ann. Oncol.20, 227–230 (2009).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Douglas PS, Middleton JP et al. Analysis of early hypertension and clinical outcome in colorectal cancer patients treated with first-line bevacizumab. J. Clin. Oncol.28(Suppl.), (2010) (Abstract 3039).
   Google Scholar
• De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS and KIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy refractory metastatic colrectal cancer; a retrospective consortium analysis. Lancet Oncol.11, 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J.17(2), 114–126 (2011).
   PubMedGoogle Scholar
• O’Connell MJ, Lavery I, Yothers G et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol.28(25), 3937–3944 (2010).
   PubMed Web of Science ®Google Scholar
• Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol.29(1), 17–24 (2010).
   PubMedGoogle Scholar
• Molinari F, Martin V, Saletti P et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer100(7), 1087–1094 (2009).
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res.16(3), 790–799 (2010).
   PubMed Web of Science ®Google Scholar
• Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J. Clin. Oncol.29(8), 1083–1090 (2011).
   PubMed Web of Science ®Google Scholar
• Rena O, Casadio C, Viano F et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur. J. Cardiothorac. Surg.21(5), 906–912 (2002).
   PubMed Web of Science ®Google Scholar
• Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br. J. Surg.91(8), 1066–1071 (2004).
   PubMedGoogle Scholar
• Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet371(9617), 1007–1016 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst.96(19), 1420–1425 (2004).
   PubMed Web of Science ®Google Scholar